.Nature Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of individuals with HER2+ innovative breast cancer and also energetic or even secure brain metastases presented steady intracranial task as well as systemic effectiveness of T-DXd.